×
About 9,338 results

ALLMedicine™ Hypertriglyceridemia Center

Research & Reviews  2,269 results

The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory fo...
https://doi.org/10.1158/1078-0432.CCR-22-2939
Clinical Cancer Research : an Official Journal of the Ame... Wang T, Sun X et. al.

Feb 4th, 2023 - To investigate the efficacy and safety of the novel orally active phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor in relapsed and/or refractory follicular lymphoma (FL) patients who had received at least two prior systemic treatments. Histol...

Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence.
https://doi.org/10.1007/s11886-022-01831-0
Current Cardiology Reports; Bhat S, Sarkar S et. al.

Feb 3rd, 2023 - Omega-3 fatty acids (n-3 FA) lower triglycerides, have anti-inflammatory properties, and improve metabolism. Clinical evidence of cardiovascular benefit with omega-3 fatty acids is mixed. We discuss mechanisms providing biological plausibility of ...

Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting...
https://doi.org/10.1097/YIC.0000000000000448
International Clinical Psychopharmacology; De Carlo V, Grancini B et. al.

Feb 3rd, 2023 - The present cross-sectional, retrospective study aimed to assess the prevalence of cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample of psychiatric patients treated with long-acting injectable antipsychotics (LAIs). The ...

Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertr...
https://doi.org/10.1097/MJT.0000000000001566
American Journal of Therapeutics; Wang YH, Liu CY et. al.

Feb 3rd, 2023 - Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertriglyceridemia in a Patient With Schizophrenia.|2023|Wang YH,Liu CY,Her YN,Wu HH,Yao CY,|

What is really new in triglyceride guidelines?
https://doi.org/10.1097/MED.0000000000000802
Current Opinion in Endocrinology, Diabetes, and Obesity; Hussain A, Al Rifai M et. al.

Feb 2nd, 2023 - In this review, we will summarize some of the landmark clinical trials of triglyceride-lowering therapies and review updates in clinical guidelines with regards to treatment of elevated triglyceride levels. Accumulating evidence from epidemiologic...

see more →

Guidelines  4 results

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Pro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.

Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole N...

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in...
https://doi.org/10.1016/j.jacc.2021.06.011
Journal of the American College of Cardiology; Virani SS, Morris PB et. al.

Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771
Current Oncology (Toronto, Ont.); Blais N, Adam JP et. al.

Jan 4th, 2021 - The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of l...

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

see more →

Drugs  909 results see all →

Clinicaltrials.gov  275 results

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05610280

Jan 27th, 2023 - This is a Phase 3, multi-center, placebo-controlled study of up to 1312 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to 8 weeks); 2)...

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05552326

Jan 26th, 2023 - This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study in up to approximately 390 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation...

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262832

Jan 25th, 2023 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
https://clinicaltrials.gov/ct2/show/NCT02262806

Jan 25th, 2023 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with lipodystrophy have leptin deficiency secondary to lack of...

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05079919

Jan 25th, 2023 - This is a multi-center, randomized, double-blind, placebo-controlled study in up to approximately 540 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the s...

see more →

News  276 results

Oral Antiviral Matches Paxlovid in High-Risk COVID
https://www.medpagetoday.com/infectiousdisease/covid19/102487

Jan 3rd, 2023 - An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from China suggested. Sus...

Metabolic syndrome may promote gout in young men
https://www.mdedge.com/rheumatology/article/260163/gout/metabolic-syndrome-may-promote-gout-young-men
Heidi Splete

Dec 15th, 2022 - Metabolic syndrome is associated with a significantly increased risk for gout in young men, but the risk can be mitigated by improvement in individual components of the syndrome, based on data from a pair of population-based studies totaling more.

Triglyceride-lowering fails to show CV benefit in large fibrate trial
https://www.mdedge.com/cardiology/article/259219/lipid-disorders/triglyceride-lowering-fails-show-cv-benefit-large-fibrate
Ted Bosworth

Nov 5th, 2022 - CHICAGO – Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite end.

Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial
https://www.medscape.com/viewarticle/983610

Nov 5th, 2022 - Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite endpoint of m...

Pyrotinib Plus Trastuzumab/Docetaxel Prolongs PFS in HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/pyrotinib-plus-trastuzumab-docetaxel-prolongs-pfs-in-her2-metastatic-breast-cancer

Oct 14th, 2022 - The addition of pyrotinib to trastuzumab (Herceptin) and docetaxel significantly improved progression-free survival (PFS) vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer, according to data from the phase 3 PH...

see more →

Patient Education  2 results see all →